Search

Your search keyword '"Chopra, Vijay"' showing total 284 results

Search Constraints

Start Over You searched for: Author "Chopra, Vijay" Remove constraint Author: "Chopra, Vijay"
284 results on '"Chopra, Vijay"'

Search Results

1. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure

2. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

3. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction

4. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

5. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

7. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

8. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

9. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial

10. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

11. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

12. Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC

13. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

14. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

15. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

16. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction:a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

17. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

18. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.

19. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction

21. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

22. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

23. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

25. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

28. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

29. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

30. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

31. Health status across major subgroups of patients with heart failure and preserved ejection fraction

33. Semaglutide in HFpEF across obesity class and by body weight reduction:a prespecified analysis of the STEP-HFpEF trial

34. Patient-Reported Versus Physician-Assessed Health Status in Heart Failure With Reduced and Preserved Ejection Fraction From ASIAN-HF Registry

35. Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus

36. A Retrospective Study on Gloriosa superbaand Its Main Active Constituents

37. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction

38. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study

39. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction

40. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction:An Analysis of the DAPA-HF Trial

41. PATIENT REPORTED VERSUS PHYSICIAN-ASSESSED HEALTH STATUS IN HEART FAILURE WITH REDUCED AND PRESERVED EJECTION FRACTION FROM ASIAN-HF REGISTRY

45. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

46. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

48. Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study

49. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

50. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction:Results of DAPA-HF

Catalog

Books, media, physical & digital resources